Technical Analysis for ONCO - Onconetix, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| New 52 Week Closing Low | Bearish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Outside Day | Range Expansion | -3.90% | |
| Wide Bands | Range Expansion | -3.90% | |
| Wide Bands | Range Expansion | -9.84% | |
| Gapped Down | Weakness | -9.84% | |
| Hammer Candlestick | Bullish | -10.20% |
| Alert | Time |
|---|---|
| Gap Up Closed | about 21 hours ago |
| Gap Up Partially Closed | about 21 hours ago |
| 60 Minute Opening Range Breakdown | about 21 hours ago |
| Down 5% | about 21 hours ago |
| Down 3% | about 21 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/30/2024
Onconetix, Inc. (formerly Blue Water Biotech, Inc. (BWV)) is a commercial stage biotechnology company focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The Company currently has Entadfi®, an FDA approved, oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, and Proclarix®, an advanced proprietary diagnostic system for screening and diagnosis for men with indeterminate Prostate Specific Antigen (PSA) assessments in prostate cancer oncology.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology FDA Disorders Prostate Cancer Urology Benign Prostatic Hyperplasia Bph Men's Health Prostate Treatment Of Benign Prostatic Hyperplasia
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology FDA Disorders Prostate Cancer Urology Benign Prostatic Hyperplasia Bph Men's Health Prostate Treatment Of Benign Prostatic Hyperplasia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 1.58 |
| 52 Week Low | 0.1001 |
| Average Volume | 381,352 |
| 200-Day Moving Average | 0.37 |
| 50-Day Moving Average | 0.15 |
| 20-Day Moving Average | 0.12 |
| 10-Day Moving Average | 0.12 |
| Average True Range | 0.01 |
| RSI (14) | 32.89 |
| ADX | 14.22 |
| +DI | 21.03 |
| -DI | 21.98 |
| Chandelier Exit (Long, 3 ATRs) | 0.13 |
| Chandelier Exit (Short, 3 ATRs) | 0.14 |
| Upper Bollinger Bands | 0.15 |
| Lower Bollinger Band | 0.10 |
| Percent B (%b) | 0.2 |
| BandWidth | 34.68 |
| MACD Line | -0.01 |
| MACD Signal Line | -0.01 |
| MACD Histogram | 0.0007 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.14 | ||||
| Resistance 3 (R3) | 0.14 | 0.13 | 0.13 | ||
| Resistance 2 (R2) | 0.13 | 0.13 | 0.13 | 0.13 | |
| Resistance 1 (R1) | 0.12 | 0.12 | 0.12 | 0.12 | 0.13 |
| Pivot Point | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 |
| Support 1 (S1) | 0.10 | 0.11 | 0.10 | 0.10 | 0.09 |
| Support 2 (S2) | 0.10 | 0.10 | 0.10 | 0.09 | |
| Support 3 (S3) | 0.09 | 0.10 | 0.09 | ||
| Support 4 (S4) | 0.09 |
